DHR 81.06 Danaher Corp $DHR Hit a 52 week high of 81.29 Currently at 81.06 -0.13 -0.16% With a day low of 81.01 and a total volume of 75,033.
DHR Danaher Corp Recent Headline News
C3 Jian Adds Two Top Oral Healthcare Professionals to Its Board of Directors
GlobeNewswire - Mon Nov 10, 5:00AM CST
C3 Jian, Inc., a private company focused on providing improved oral healthcare through new pharmaceutical products, announced the appointment of Steven J. Semmelmayer and Richard P. Bisson to its Board of Directors.
DHR: 81.34 (+0.15)
Danaher to Webcast Investor and Analyst Meeting
Thomson Reuters ONE - Fri Nov 07, 7:01AM CST
This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
DHR: 81.34 (+0.15)
Global Cell Expansion Market Outlook 2019 - Product, Cell Type, Application & End User Analysis of the $14 Billion Industry
M2 - Fri Nov 07, 6:41AM CST
Research and Markets (http://www.researchandmarkets.com/research/hw245b/cell_expansion) has announced the addition of the "Cell Expansion Market by Product , Cell Type, Application, End User - Forecast to 2019" report to their offering. The global cell expansion market is expected to reach $14.8 billion by 2019 from $6.0 billion in 2014, growing at a CAGR of 19.7% from 2014 to 2019 The global cell expansion market is categorized on the basis of product, cell type, application, end user, and geography. The human cell expansion segment is expected to register the highest growth rate in the cell expansion market, by cell type, during the forecast period. Its favorable growth is attributed to increasing focus on human stem cell research and the increasing usage of stem cell for treating various disorders. Also, the market of regenerative medicines is expected to grow at highest CAGR in the cell expansion application market. This growth is attributed to the increasing government investments and technological advancements in this segment. Major factors contributing to growth of the cell expansion market include the increasing research activities, technological advancements, high prevalence of chronic diseases, and rising investments by companies are likely to propel the growth of this market. Furthermore, government support in the form of funding is another major factor providing impetus for growth of this market. For instance, in April 2013, the Scottish government granted $13.5 million to the College of Life Sciences at the University of Dundee (Scotland) for development of advanced stem cell technology. The relatively untapped markets of the Asian region and advent of 3D technology in cell expansion have opened an array of opportunities for the cell expansion market. However, the high cost of instruments and ethical concerns are expected to restrain the growth of this market. Scope of the Report Product - Reagent - Media - Serum - Bioreactors - Centrifuge Cell Type - Human - Animal Application - Stem Cell Research - Regenerative Medicine - Clinical Diagnostics End User - Hospital - Biotechnology - Cell Bank) Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Industry Trends 7 Cell Expansion Market, By Product 8 Cell Expansion Market, By Cell Type 9 Cell Expansion Market, By Application 10 Cell Expansion Market, By End User 11 Cell Expansion Market, By Geography 12 Competitive Landscape 13 Company Profiles - Beckman Coulter (Subsidiary of Danaher Corporation) - Becton Dickinson and Company - Corning Incorporated - Ge Healthcare (A Fully Owned Subsidiary of General Electric Company) - Merck Millipore (A Segment of Merck Kgaa) - Miltenyi Biotec - Sigma-Aldrich Corporation - Stemcell Technologies - Terumo BCT (A Subsidiary of Terumo Corporation) - Thermo Fisher Scientific, Inc. For more information visit http://www.researchandmarkets.com/research/hw..._expansion
GE: 26.49 (+0.08), SIAL: 135.60 (+0.26), MRK: 57.99 (-1.35), DHR: 81.34 (+0.15)
Horizon Pharma elects John J. Kody as EVP
M2 - Thu Nov 06, 7:22AM CST
Biopharmaceutical company Horizon Pharma (NasdaqGS:HZNP) said on Thursday that its board has named John J. Kody as its executive vice president and chief commercial officer, as well as to its executive committee.
HZNP: 12.95 (-0.04), DHR: 81.34 (+0.15)
Global Polymerase Chain Reaction (PCR) Market 2014-2018: Key Vendors are Abbott Laboratories, Agilent Technologies, Bio-Rad Laboratories, GE Healthcare and Thermo Fisher Scientific
M2 - Thu Nov 06, 5:38AM CST
Research and Markets (http://www.researchandmarkets.com/research/slnt9m/global_polymerase) has announced the addition of the "Global Polymerase Chain Reaction (PCR) Market 2014-2018" report to their offering. Polymerase Chain Reaction (PCR) is a technique of molecular genetics, which allows amplification and analysis of nucleic acid. It is very precise, specific and accurate technique used to amplify a specific DNA target from a mixture of DNA molecules. It is used in a wide array of applications in research and diagnosis, including genetic engineering, cloning, sequencing, diagnosis, genotyping, and many other areas. Advances in PCR technology and tools provide high reproducibility within a short period of time. Depending on the requirement, PCR involves different types of reagents, consumables and instruments to process the sample. Advanced software helps to analyze the data generated from the sample processing. The analysts forecast the Global Polymerase Chain Reaction market to grow at a CAGR of 9.19 percent over the period 2013-2018. This report covers the present scenario and the growth prospects of the Global Polymerase Chain Reaction market for the period 2014-2018. To calculate the market size, the report considers revenue generated from sales of products used in PCR. The products considered within the scope of the report are PCR reagents and consumables, instruments, and software and services, which are required to perform PCR. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Market Segmentation by Product 08. Geographical Segmentation 09. Buying Criteria 10. Market Growth Drivers 11. Drivers and their Impact 12. Market Challenges 13. Impact of Drivers and Challenges 14. Market Trends 15. Trends and their Impact 16. Vendor Landscape 17. Key Vendor Analysis 18. Other Reports in this Series Companies Mentioned: - Abbott Laboratories - Affimetrix - Agilent Technologies - BD - Bio-Rad Laboratories - Cepheid - Danaher - Eppendorf - F. Hoffmann-La Roche - Fluidigm - GE Healthcare - Harvard Bioscience - Illumin - PerkinElmer - Promega - Qiagen - RainDanceTechnologies - Sigma-Aldrich - Takara Bio - Thermo Fisher Scientific For more information visit http://www.researchandmarkets.com/research/sl...polymerase
ABT: 43.52 (+0.15), A: 41.27 (+0.34), CPHD: 52.14 (+0.45), DHR: 81.34 (+0.15), PKI: 43.93 (+0.12)
Horizon Pharma plc Appoints John J. Kody as Executive Vice President and Chief Commercial Officer
Marketwired - Thu Nov 06, 5:30AM CST
Horizon Pharma plc (NASDAQ: HZNP), a specialty biopharmaceutical company with a portfolio of products in arthritis, inflammation and orphan diseases, announced today the Company's Board has appointed John J. Kody, executive vice president and chief commercial officer, reporting to Timothy P. Walbert, chairman, president and chief executive officer, effective November 24, 2014. Mr. Kody brings more than 20 years of executive, general management and commercial experience in the pharmaceutical, biotechnology and medical device industries to Horizon Pharma. He will also be a member of the Company's executive committee.
HZNP: 12.95 (-0.04), DHR: 81.34 (+0.15)
Global Drug Abuse Testing Market Outlook 2018 - Increase in Number of Collaborations and M&A
M2 - Thu Nov 06, 5:11AM CST
Research and Markets (http://www.researchandmarkets.com/research/dtmmdp/global_drug_abuse) has announced the addition of the "Global Drug Abuse Testing Market 2014-2018" report to their offering. The Global Drug Abuse Testing market to grow at a CAGR of 4.71% over the period 2013-2018 To calculate the market size, the report considers the revenue generated from sales of drug abuse testing solutions, which includes drug abuse testing kits and systems. The technologies primarily considered in the report are immunoassay and chromatography. One of the major trends upcoming in the market is the increase in the number of collaborations and M&A in the market. This strategy helps vendors to expand their portfolio as well as improve the quality and performance of their products. According to the report, the rising consumption of illicit drugs is a major driver in the Global Drug Abuse Testing market as the use of illicit drugs in developed as well as in developing countries is increasing worldwide. Further, the report states that one of the key challenges that the market faces is the inability of drug abuse testing products to detect low-dose designer drugs. The detection of designer drugs such as ecstasy, Rohypnol, and LSD is very difficult. Key Vendors - Bio-Rad Laboratories - Danaher - F. Hoffmann-La Roche - Siemens - Thermo Fisher Scientific Other Prominent Vendors - Abbott Laboratories - Agilent Technologies - Alere - Biomedical Diagnostics - Branan Medical - OraSure Technologies - PerkinElmer - Psychemedics - Quest Diagnostic - Randox Laboratories - Sigma-Aldrich - Sonic Healthcare - Waters Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Overview - Market Landscape - Market Segmentation by Technique - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/dt...drug_abuse
PMD: 14.93 (+0.14), ABT: 43.52 (+0.15), A: 41.27 (+0.34), DHR: 81.34 (+0.15), PKI: 43.93 (+0.12), OSUR: 8.96 (-0.02)
New Agreement, Financial Results, Senior Level Appointment, and Award - Research Reports on Danaher, Cummins, Parker, Raytheon and Fluor
PR Newswire - Wed Nov 05, 7:55AM CST
Today, Analysts Review released its research reports regarding Danaher Corporation (NYSE: DHR), Cummins Inc. (NYSE: CMI), Parker-Hannifin Corporation (NYSE: PH), Raytheon Company (NYSE: RTN) and Fluor Corporation (NYSE: FLR). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7705-100free.
PH: 128.61 (+0.11), NTCT: 38.05 (-0.19), CMI: 146.01 (-0.03), RTN: 103.55 (-0.81), FLR: 66.48 (+0.19), DHR: 81.34 (+0.15)
US Clinical Chemistry and Immunodiagnostic Market 2014: Sales Forecasts, Supplier Shares, Competitive Strategies
M2 - Wed Nov 05, 3:41AM CST
Research and Markets (http://www.researchandmarkets.com/research/c8rfzx/us_clinical) has announced the addition of the "US Clinical Chemistry and Immunodiagnostic Market 2014: Sales Forecasts, Supplier Shares, Competitive Strategies" report to their offering. US Clinical Chemistry and Immunodiagnostic Market 2014: Sales Forecasts, Supplier Shares, Competitive Strategiesis a new strategic analysis of major business opportunities emerging in the US clinical chemistry and immunodiagnostic markets during the next five years. The report explores future trends in the US market provides estimates of the specimen, test and sales volumes, as well as major suppliers&rsquo sales and market shares compares features of leading analyzers profiles key competitors and identifies specific product and marketing opportunities emerging during the next five years. The report provides five-year volume and sales forecasts for over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein and abused drug assays performed in hospitals, commercial laboratories, physician offices, and ambulatory care centers, including controls, calibrators and consumables. Tests Analyzed in the Report: - Routine Clinical Chemistry - Therapeutic Drug Monitoring (TDM) - Endocrine Function - Tumor Markers and Special Chemistry - Immunoproteins - Drugs of Abuse The companies analyzed in the report include: - Abbott - AdnaGen - Agilent - Alere - Beckman Coulter/Danaher - Biomedical Diagnostics - bioMerieux - Bio-Rad - DiaSorin - Eiken - Fujirebio/Innogenetics - IL - Kyowa Medex - Ortho-Clinical Diagnotics - Roche - Siemens - Sysmex - Thermo Fisher - Tosoh - Wako - Wallac/PE For more information visit http://www.researchandmarkets.com/research/c8...s_clinical
DHR: 81.34 (+0.15)
Research and Markets: Global Tissue Diagnostics Market 2014-2018: Key Vendors are Abbott Laboratories, Agilent Technologies, Danaher and F. Hoffmann-La Roche
Business Wire - Tue Nov 04, 3:42AM CST
Research and Markets (http://www.researchandmarkets.com/research/3fxsfx/global_tissue) has announced the addition of the "Global Tissue Diagnostics Market 2014-2018" report to their offering.
A: 41.27 (+0.34), DHR: 81.34 (+0.15)
Artisan Business Group to host the Accelerated EB-5 Capital Raising Workshop in Seattle
PRWeb - Fri Oct 31, 7:31AM CDT
Artisan Business Group Inc. is to host the Accelerated EB-5 Capital Raising Workshop December 3, 2014 in Seattle, Washington. The Seattle Accelerated EB-5 Capital Raising Process Workshop will focus on exploring alternative finance through EB-5 immigrant investors program.
DHR: 81.34 (+0.15)
Global Coagulation Testing Market 2014-2018 - Increase in Prevalence of CVD
M2 - Thu Oct 30, 9:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kdcwwv/global) has announced the addition of the "Global Coagulation Testing Market 2014-2018" report to their offering. Coagulation tests help in measuring the clotting ability of blood. Clotting is the process of blood converting from liquid into gel form. Coagulation tests are performed to analyze clotting disorders such as hemorrhage and thrombosis. Coagulation tests include complete blood count, factor V assay, fibrinogen level, prothrombin time, platelet count, thrombin time, and bleeding time. Coagulation testing analyzers play a major role in improving patients' quality of life. An expansion of some of the economies in the APAC region is one of the main trends seen in this market. Governments in emerging countries are making efforts to improve healthcare infrastructure, which has benefited the Coagulation Testing market. According to the report, one of the major drivers in the market is the increase in the prevalence of cardiovascular disease. CVD deaths occur almost equally in men and women and it is predicted that by 2030 almost 23.6 million people will die from CVD. An increase in the prevalence of CVD has led to the development of coagulation testing products, and thus, the growth of the market. Further, the report states that one of the major challenges in the market is the high cost incurred in R&D activities. Many big vendors are facing the frequent elimination of coagulation testing analyzer products because of rapid developments with respect to the technological aspects of coagulation testing analyzers. The Global Coagulation Testing market can be segmented into the revenue generated from end- user application such as: - Point-of-Care Coagulation Testing - Home Diagnostics Key Vendors - Abbott Laboratories - Danaher - F. Hoffmann-La Roche - Sysmex Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Coagulation Testing Application - Market Landscape - Market Segmentation by Technology - Market Segmentation by Types Coagulation Tests - Market Segmentation by End-users - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape For more information visit http://www.researchandmarkets.com/research/kdcwwv/global
ABT: 43.52 (+0.15), DHR: 81.34 (+0.15)
GTCR reports sale of Devicor Medical Products
M2 - Wed Oct 29, 5:09AM CDT
Private equity firm GTCR revealed on Tuesday that its Devicor Medical Products portfolio company has signed an agreement to be acquired by Danaher's (NYSE
HR) Leica Biosystems for an undisclosed value.
DHR: 81.34 (+0.15)
Watch for Danaher to Potentially Pullback After Gaining 2.38% Yesterday
Comtex SmarTrend(R) - Tue Oct 28, 5:21PM CDT
Danaher (NYSE HR) traded in a range yesterday that spanned from a low of $78.31 to a high of $79.77. Yesterday, the shares gained 2.4%, which took the trading range above the 3-day high of $78.00 on volume of 3.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
DHR: 81.34 (+0.15)
Danaher Rises 2.38% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Tue Oct 28, 5:20PM CDT
Danaher (NYSE HR) traded in a range yesterday that spanned from a low of $78.31 to a high of $79.77. Yesterday, the shares gained 2.4%, which took the trading range above the 3-day high of $78.00 on volume of 3.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
DHR: 81.34 (+0.15)
Earnings Notes - Danaher
PR Newswire - Tue Oct 28, 8:30AM CDT
Investor-Edge.com has issued free earnings notes on Danaher Corp. (NYSE: DHR). On October 16, 2014, the company reported its financial results for Q3 FY14 (period ended September 26, 2014). Click on http://www.investor-edge.com/FreeReports to read our free earnings review on Danaher Corp. During Q3 FY14, Danaher Corp.'s revenues and core revenues grew 4.5% and 3%, respectively, on a Y-o-Y basis, and its diluted EPS surged 13% from the preceding year quarter. Our free coverage report can be accessed at:
DHR: 81.34 (+0.15)
GTCR Announces Sale of Devicor Medical Products
Business Wire - Tue Oct 28, 6:31AM CDT
GTCR, a leading private equity firm, announced today that Devicor Medical Products ("Devicor" or the "Company"
, a GTCR portfolio company, has signed an agreement to be acquired by Danaher Corporation's (NYSE: DHR) Leica Biosystems, a leading provider of anatomical pathology solutions and automation used to advance cancer diagnostics.
JNJ: 107.96 (-0.24), DHR: 81.34 (+0.15)
Leica Biosystems to Acquire Devicor Medical Products, Inc.
PR Newswire - Tue Oct 28, 5:55AM CDT
Leica Biosystems, a global leader in anatomic pathology laboratory solutions and instruments, announced today that it has entered into a definitive agreement to acquire Devicor Medical Products, Inc.
DHR: 81.34 (+0.15)
Roper Q3 Earnings Beat, Revenues Miss; Outlook Positive - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 27, 11:20AM CDT
Roper Industries Inc. (ROP) reported third-quarter 2014 non-GAAP earnings of $1.54 per share, beating the Zacks Consensus Estimate by a penny.
ROP: 158.25 (-0.01), IR: 63.73 (+0.22), DOV: 81.52 (-0.01), DHR: 81.34 (+0.15)
Financial Results, Product Testing, Dividends, Executive Recognitions, and Community Initiatives - Research Reports on Danaher, General Dynamics, Ingersoll-Rand, Lennar and Stanley Black & Decker
PR Newswire - Mon Oct 27, 7:40AM CDT
Today, Analysts Review released its research reports regarding Danaher Corp. (NYSE: DHR), General Dynamics Corporation (NYSE: GD), Ingersoll-Rand Plc (NYSE: IR), Lennar Corp. (NYSE: LEN) and Stanley Black & Decker, Inc. (NYSE: SWK). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7436-100free.
SWK: 95.66 (+0.65), GD: 140.91 (+0.77), LEN: 45.69 (+1.15), IR: 63.73 (+0.22), DHR: 81.34 (+0.15)
DHR Danaher Corp Recent Headline News
C3 Jian Adds Two Top Oral Healthcare Professionals to Its Board of Directors
GlobeNewswire - Mon Nov 10, 5:00AM CST
C3 Jian, Inc., a private company focused on providing improved oral healthcare through new pharmaceutical products, announced the appointment of Steven J. Semmelmayer and Richard P. Bisson to its Board of Directors.
DHR: 81.34 (+0.15)
Danaher to Webcast Investor and Analyst Meeting
Thomson Reuters ONE - Fri Nov 07, 7:01AM CST
This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
DHR: 81.34 (+0.15)
Global Cell Expansion Market Outlook 2019 - Product, Cell Type, Application & End User Analysis of the $14 Billion Industry
M2 - Fri Nov 07, 6:41AM CST
Research and Markets (http://www.researchandmarkets.com/research/hw245b/cell_expansion) has announced the addition of the "Cell Expansion Market by Product , Cell Type, Application, End User - Forecast to 2019" report to their offering. The global cell expansion market is expected to reach $14.8 billion by 2019 from $6.0 billion in 2014, growing at a CAGR of 19.7% from 2014 to 2019 The global cell expansion market is categorized on the basis of product, cell type, application, end user, and geography. The human cell expansion segment is expected to register the highest growth rate in the cell expansion market, by cell type, during the forecast period. Its favorable growth is attributed to increasing focus on human stem cell research and the increasing usage of stem cell for treating various disorders. Also, the market of regenerative medicines is expected to grow at highest CAGR in the cell expansion application market. This growth is attributed to the increasing government investments and technological advancements in this segment. Major factors contributing to growth of the cell expansion market include the increasing research activities, technological advancements, high prevalence of chronic diseases, and rising investments by companies are likely to propel the growth of this market. Furthermore, government support in the form of funding is another major factor providing impetus for growth of this market. For instance, in April 2013, the Scottish government granted $13.5 million to the College of Life Sciences at the University of Dundee (Scotland) for development of advanced stem cell technology. The relatively untapped markets of the Asian region and advent of 3D technology in cell expansion have opened an array of opportunities for the cell expansion market. However, the high cost of instruments and ethical concerns are expected to restrain the growth of this market. Scope of the Report Product - Reagent - Media - Serum - Bioreactors - Centrifuge Cell Type - Human - Animal Application - Stem Cell Research - Regenerative Medicine - Clinical Diagnostics End User - Hospital - Biotechnology - Cell Bank) Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Industry Trends 7 Cell Expansion Market, By Product 8 Cell Expansion Market, By Cell Type 9 Cell Expansion Market, By Application 10 Cell Expansion Market, By End User 11 Cell Expansion Market, By Geography 12 Competitive Landscape 13 Company Profiles - Beckman Coulter (Subsidiary of Danaher Corporation) - Becton Dickinson and Company - Corning Incorporated - Ge Healthcare (A Fully Owned Subsidiary of General Electric Company) - Merck Millipore (A Segment of Merck Kgaa) - Miltenyi Biotec - Sigma-Aldrich Corporation - Stemcell Technologies - Terumo BCT (A Subsidiary of Terumo Corporation) - Thermo Fisher Scientific, Inc. For more information visit http://www.researchandmarkets.com/research/hw..._expansion
GE: 26.49 (+0.08), SIAL: 135.60 (+0.26), MRK: 57.99 (-1.35), DHR: 81.34 (+0.15)
Horizon Pharma elects John J. Kody as EVP
M2 - Thu Nov 06, 7:22AM CST
Biopharmaceutical company Horizon Pharma (NasdaqGS:HZNP) said on Thursday that its board has named John J. Kody as its executive vice president and chief commercial officer, as well as to its executive committee.
HZNP: 12.95 (-0.04), DHR: 81.34 (+0.15)
Global Polymerase Chain Reaction (PCR) Market 2014-2018: Key Vendors are Abbott Laboratories, Agilent Technologies, Bio-Rad Laboratories, GE Healthcare and Thermo Fisher Scientific
M2 - Thu Nov 06, 5:38AM CST
Research and Markets (http://www.researchandmarkets.com/research/slnt9m/global_polymerase) has announced the addition of the "Global Polymerase Chain Reaction (PCR) Market 2014-2018" report to their offering. Polymerase Chain Reaction (PCR) is a technique of molecular genetics, which allows amplification and analysis of nucleic acid. It is very precise, specific and accurate technique used to amplify a specific DNA target from a mixture of DNA molecules. It is used in a wide array of applications in research and diagnosis, including genetic engineering, cloning, sequencing, diagnosis, genotyping, and many other areas. Advances in PCR technology and tools provide high reproducibility within a short period of time. Depending on the requirement, PCR involves different types of reagents, consumables and instruments to process the sample. Advanced software helps to analyze the data generated from the sample processing. The analysts forecast the Global Polymerase Chain Reaction market to grow at a CAGR of 9.19 percent over the period 2013-2018. This report covers the present scenario and the growth prospects of the Global Polymerase Chain Reaction market for the period 2014-2018. To calculate the market size, the report considers revenue generated from sales of products used in PCR. The products considered within the scope of the report are PCR reagents and consumables, instruments, and software and services, which are required to perform PCR. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Market Segmentation by Product 08. Geographical Segmentation 09. Buying Criteria 10. Market Growth Drivers 11. Drivers and their Impact 12. Market Challenges 13. Impact of Drivers and Challenges 14. Market Trends 15. Trends and their Impact 16. Vendor Landscape 17. Key Vendor Analysis 18. Other Reports in this Series Companies Mentioned: - Abbott Laboratories - Affimetrix - Agilent Technologies - BD - Bio-Rad Laboratories - Cepheid - Danaher - Eppendorf - F. Hoffmann-La Roche - Fluidigm - GE Healthcare - Harvard Bioscience - Illumin - PerkinElmer - Promega - Qiagen - RainDanceTechnologies - Sigma-Aldrich - Takara Bio - Thermo Fisher Scientific For more information visit http://www.researchandmarkets.com/research/sl...polymerase
ABT: 43.52 (+0.15), A: 41.27 (+0.34), CPHD: 52.14 (+0.45), DHR: 81.34 (+0.15), PKI: 43.93 (+0.12)
Horizon Pharma plc Appoints John J. Kody as Executive Vice President and Chief Commercial Officer
Marketwired - Thu Nov 06, 5:30AM CST
Horizon Pharma plc (NASDAQ: HZNP), a specialty biopharmaceutical company with a portfolio of products in arthritis, inflammation and orphan diseases, announced today the Company's Board has appointed John J. Kody, executive vice president and chief commercial officer, reporting to Timothy P. Walbert, chairman, president and chief executive officer, effective November 24, 2014. Mr. Kody brings more than 20 years of executive, general management and commercial experience in the pharmaceutical, biotechnology and medical device industries to Horizon Pharma. He will also be a member of the Company's executive committee.
HZNP: 12.95 (-0.04), DHR: 81.34 (+0.15)
Global Drug Abuse Testing Market Outlook 2018 - Increase in Number of Collaborations and M&A
M2 - Thu Nov 06, 5:11AM CST
Research and Markets (http://www.researchandmarkets.com/research/dtmmdp/global_drug_abuse) has announced the addition of the "Global Drug Abuse Testing Market 2014-2018" report to their offering. The Global Drug Abuse Testing market to grow at a CAGR of 4.71% over the period 2013-2018 To calculate the market size, the report considers the revenue generated from sales of drug abuse testing solutions, which includes drug abuse testing kits and systems. The technologies primarily considered in the report are immunoassay and chromatography. One of the major trends upcoming in the market is the increase in the number of collaborations and M&A in the market. This strategy helps vendors to expand their portfolio as well as improve the quality and performance of their products. According to the report, the rising consumption of illicit drugs is a major driver in the Global Drug Abuse Testing market as the use of illicit drugs in developed as well as in developing countries is increasing worldwide. Further, the report states that one of the key challenges that the market faces is the inability of drug abuse testing products to detect low-dose designer drugs. The detection of designer drugs such as ecstasy, Rohypnol, and LSD is very difficult. Key Vendors - Bio-Rad Laboratories - Danaher - F. Hoffmann-La Roche - Siemens - Thermo Fisher Scientific Other Prominent Vendors - Abbott Laboratories - Agilent Technologies - Alere - Biomedical Diagnostics - Branan Medical - OraSure Technologies - PerkinElmer - Psychemedics - Quest Diagnostic - Randox Laboratories - Sigma-Aldrich - Sonic Healthcare - Waters Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Overview - Market Landscape - Market Segmentation by Technique - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/dt...drug_abuse
PMD: 14.93 (+0.14), ABT: 43.52 (+0.15), A: 41.27 (+0.34), DHR: 81.34 (+0.15), PKI: 43.93 (+0.12), OSUR: 8.96 (-0.02)
New Agreement, Financial Results, Senior Level Appointment, and Award - Research Reports on Danaher, Cummins, Parker, Raytheon and Fluor
PR Newswire - Wed Nov 05, 7:55AM CST
Today, Analysts Review released its research reports regarding Danaher Corporation (NYSE: DHR), Cummins Inc. (NYSE: CMI), Parker-Hannifin Corporation (NYSE: PH), Raytheon Company (NYSE: RTN) and Fluor Corporation (NYSE: FLR). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7705-100free.
PH: 128.61 (+0.11), NTCT: 38.05 (-0.19), CMI: 146.01 (-0.03), RTN: 103.55 (-0.81), FLR: 66.48 (+0.19), DHR: 81.34 (+0.15)
US Clinical Chemistry and Immunodiagnostic Market 2014: Sales Forecasts, Supplier Shares, Competitive Strategies
M2 - Wed Nov 05, 3:41AM CST
Research and Markets (http://www.researchandmarkets.com/research/c8rfzx/us_clinical) has announced the addition of the "US Clinical Chemistry and Immunodiagnostic Market 2014: Sales Forecasts, Supplier Shares, Competitive Strategies" report to their offering. US Clinical Chemistry and Immunodiagnostic Market 2014: Sales Forecasts, Supplier Shares, Competitive Strategiesis a new strategic analysis of major business opportunities emerging in the US clinical chemistry and immunodiagnostic markets during the next five years. The report explores future trends in the US market provides estimates of the specimen, test and sales volumes, as well as major suppliers&rsquo sales and market shares compares features of leading analyzers profiles key competitors and identifies specific product and marketing opportunities emerging during the next five years. The report provides five-year volume and sales forecasts for over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein and abused drug assays performed in hospitals, commercial laboratories, physician offices, and ambulatory care centers, including controls, calibrators and consumables. Tests Analyzed in the Report: - Routine Clinical Chemistry - Therapeutic Drug Monitoring (TDM) - Endocrine Function - Tumor Markers and Special Chemistry - Immunoproteins - Drugs of Abuse The companies analyzed in the report include: - Abbott - AdnaGen - Agilent - Alere - Beckman Coulter/Danaher - Biomedical Diagnostics - bioMerieux - Bio-Rad - DiaSorin - Eiken - Fujirebio/Innogenetics - IL - Kyowa Medex - Ortho-Clinical Diagnotics - Roche - Siemens - Sysmex - Thermo Fisher - Tosoh - Wako - Wallac/PE For more information visit http://www.researchandmarkets.com/research/c8...s_clinical
DHR: 81.34 (+0.15)
Research and Markets: Global Tissue Diagnostics Market 2014-2018: Key Vendors are Abbott Laboratories, Agilent Technologies, Danaher and F. Hoffmann-La Roche
Business Wire - Tue Nov 04, 3:42AM CST
Research and Markets (http://www.researchandmarkets.com/research/3fxsfx/global_tissue) has announced the addition of the "Global Tissue Diagnostics Market 2014-2018" report to their offering.
A: 41.27 (+0.34), DHR: 81.34 (+0.15)
Artisan Business Group to host the Accelerated EB-5 Capital Raising Workshop in Seattle
PRWeb - Fri Oct 31, 7:31AM CDT
Artisan Business Group Inc. is to host the Accelerated EB-5 Capital Raising Workshop December 3, 2014 in Seattle, Washington. The Seattle Accelerated EB-5 Capital Raising Process Workshop will focus on exploring alternative finance through EB-5 immigrant investors program.
DHR: 81.34 (+0.15)
Global Coagulation Testing Market 2014-2018 - Increase in Prevalence of CVD
M2 - Thu Oct 30, 9:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kdcwwv/global) has announced the addition of the "Global Coagulation Testing Market 2014-2018" report to their offering. Coagulation tests help in measuring the clotting ability of blood. Clotting is the process of blood converting from liquid into gel form. Coagulation tests are performed to analyze clotting disorders such as hemorrhage and thrombosis. Coagulation tests include complete blood count, factor V assay, fibrinogen level, prothrombin time, platelet count, thrombin time, and bleeding time. Coagulation testing analyzers play a major role in improving patients' quality of life. An expansion of some of the economies in the APAC region is one of the main trends seen in this market. Governments in emerging countries are making efforts to improve healthcare infrastructure, which has benefited the Coagulation Testing market. According to the report, one of the major drivers in the market is the increase in the prevalence of cardiovascular disease. CVD deaths occur almost equally in men and women and it is predicted that by 2030 almost 23.6 million people will die from CVD. An increase in the prevalence of CVD has led to the development of coagulation testing products, and thus, the growth of the market. Further, the report states that one of the major challenges in the market is the high cost incurred in R&D activities. Many big vendors are facing the frequent elimination of coagulation testing analyzer products because of rapid developments with respect to the technological aspects of coagulation testing analyzers. The Global Coagulation Testing market can be segmented into the revenue generated from end- user application such as: - Point-of-Care Coagulation Testing - Home Diagnostics Key Vendors - Abbott Laboratories - Danaher - F. Hoffmann-La Roche - Sysmex Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Coagulation Testing Application - Market Landscape - Market Segmentation by Technology - Market Segmentation by Types Coagulation Tests - Market Segmentation by End-users - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape For more information visit http://www.researchandmarkets.com/research/kdcwwv/global
ABT: 43.52 (+0.15), DHR: 81.34 (+0.15)
GTCR reports sale of Devicor Medical Products
M2 - Wed Oct 29, 5:09AM CDT
Private equity firm GTCR revealed on Tuesday that its Devicor Medical Products portfolio company has signed an agreement to be acquired by Danaher's (NYSE
HR) Leica Biosystems for an undisclosed value. DHR: 81.34 (+0.15)
Watch for Danaher to Potentially Pullback After Gaining 2.38% Yesterday
Comtex SmarTrend(R) - Tue Oct 28, 5:21PM CDT
Danaher (NYSE
HR) traded in a range yesterday that spanned from a low of $78.31 to a high of $79.77. Yesterday, the shares gained 2.4%, which took the trading range above the 3-day high of $78.00 on volume of 3.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious. DHR: 81.34 (+0.15)
Danaher Rises 2.38% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Tue Oct 28, 5:20PM CDT
Danaher (NYSE
HR) traded in a range yesterday that spanned from a low of $78.31 to a high of $79.77. Yesterday, the shares gained 2.4%, which took the trading range above the 3-day high of $78.00 on volume of 3.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious. DHR: 81.34 (+0.15)
Earnings Notes - Danaher
PR Newswire - Tue Oct 28, 8:30AM CDT
Investor-Edge.com has issued free earnings notes on Danaher Corp. (NYSE: DHR). On October 16, 2014, the company reported its financial results for Q3 FY14 (period ended September 26, 2014). Click on http://www.investor-edge.com/FreeReports to read our free earnings review on Danaher Corp. During Q3 FY14, Danaher Corp.'s revenues and core revenues grew 4.5% and 3%, respectively, on a Y-o-Y basis, and its diluted EPS surged 13% from the preceding year quarter. Our free coverage report can be accessed at:
DHR: 81.34 (+0.15)
GTCR Announces Sale of Devicor Medical Products
Business Wire - Tue Oct 28, 6:31AM CDT
GTCR, a leading private equity firm, announced today that Devicor Medical Products ("Devicor" or the "Company"
, a GTCR portfolio company, has signed an agreement to be acquired by Danaher Corporation's (NYSE: DHR) Leica Biosystems, a leading provider of anatomical pathology solutions and automation used to advance cancer diagnostics. JNJ: 107.96 (-0.24), DHR: 81.34 (+0.15)
Leica Biosystems to Acquire Devicor Medical Products, Inc.
PR Newswire - Tue Oct 28, 5:55AM CDT
Leica Biosystems, a global leader in anatomic pathology laboratory solutions and instruments, announced today that it has entered into a definitive agreement to acquire Devicor Medical Products, Inc.
DHR: 81.34 (+0.15)
Roper Q3 Earnings Beat, Revenues Miss; Outlook Positive - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 27, 11:20AM CDT
Roper Industries Inc. (ROP) reported third-quarter 2014 non-GAAP earnings of $1.54 per share, beating the Zacks Consensus Estimate by a penny.
ROP: 158.25 (-0.01), IR: 63.73 (+0.22), DOV: 81.52 (-0.01), DHR: 81.34 (+0.15)
Financial Results, Product Testing, Dividends, Executive Recognitions, and Community Initiatives - Research Reports on Danaher, General Dynamics, Ingersoll-Rand, Lennar and Stanley Black & Decker
PR Newswire - Mon Oct 27, 7:40AM CDT
Today, Analysts Review released its research reports regarding Danaher Corp. (NYSE: DHR), General Dynamics Corporation (NYSE: GD), Ingersoll-Rand Plc (NYSE: IR), Lennar Corp. (NYSE: LEN) and Stanley Black & Decker, Inc. (NYSE: SWK). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7436-100free.
SWK: 95.66 (+0.65), GD: 140.91 (+0.77), LEN: 45.69 (+1.15), IR: 63.73 (+0.22), DHR: 81.34 (+0.15)
